Tang-Du Hospital: Carcinoma, Non-Small-Cell Lung trials

The registry lists 19 Carcinoma, Non-Small-Cell Lung studies with Tang-Du Hospital as lead sponsor. 9 are open to participants now and 0 have results posted.

Phase 1 1Phase 2 7Phase 3 2Phase 4 1No phase 9(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Serplulimab Monotherapy in Elderly Patients With NSCLC and PD-L1 TPS ≥ 50%RecruitingNCT07596121Phase 2
• Iparomlimab and Tuvonralimab Plus Chemotherapy Before Surgery for Stage III Lung CancerNot yet recruitingNCT07538193Not applicable
• Neoadjuvant Therapy With Ensartinib Combined With Chemotherapy for ALK-positive Non - Small Cell Lung Cancer (NSCLC)RecruitingNCT07354061Phase 1/2
• Anesthesia Comparison in Early-stage Small NSCLC: A Multicenter RCTNot yet recruitingNCT07327736Not applicable
• This is a Two-cohort, Exploratory Clinical Study Assessing the Activity of Benmelstobart Alone or Combined with Anlotinib Administered Prior to Surgery in Terms of Pathological Complete ResponseNot yet recruitingNCT06851169Phase 2
• A Study to Prospectively Validate Blood Markers Associated With Differences in Efficacy of Neoadjuvant Therapy for NSCLCNot yet recruitingNCT06503042
• A Prospective Cohort Study of Neoadjuvant Chemotherapy Plus Sintillumab in the Treatment of Resectable NSCLCNot yet recruitingNCT06485557Phase 3
• Neoadjuvant/Adjuvant Tislelizumab Combined With Anlotinib and Platinum Doublet Chemotherapy With Resectable NSCLCNot yet recruitingNCT06475755Phase 2
• An Observational Study of Furmonertinib for EGFR Mutation-positive NSCLC Patients With Brain MetastasisRecruitingNCT06352502
• Neoadjuvant Furmonertinib and Cisplatin/Pemetrexed as in EGFR Mutated Stage IIA-IIIB Resectable NSCLC (FORESEE)Active, not recruitingNCT05430802Phase 2
• Penpulimab Combined With Anlotinib in Neoadjuvant Treatment of Resectable Non-small Cell Lung CancerStatus unknownNCT05387109Phase 4
• Clinical Value of MRD Monitoring for Adjuvant Therapy in Postoperative NSCLCStatus unknownNCT05167604
• Toripalimab in Combination With Platinum-based Chemotherapy for Mutation-negative Stage IV Oligometastatic NSCLCStatus unknownNCT05055583Phase 2
• A Neoadjuvant Study of Sintilimab Plus Platinum Doublet Chemotherapy in IIIA(N2) Stage NSCLCStatus unknownNCT04840290Phase 3
• Camrelizumab Combined With Albumin-bound Paclitaxel and Platinum in Neoadjuvant Treatment of Resectable NSCLCStatus unknownNCT04338620Phase 2
• Is Video-assisted Thoracoscopic Lobectomy a Clinical Alternative for Surgically Resectable Pathologic N2 NSCLC PatientsCompletedNCT03613467
• A Study to Explore Prognoses of the Patients With N2 Non-small Cell Lung CancerCompletedNCT03451526
• A Study to Explore Prognoses of NSCLC Patients Complicated With OligometastasesStatus unknownNCT03427541
• A Study to Evaluate Effectiveness and Safety of Tyrosine Kinase InhibitorsStatus unknownNCT03424980